Biopharma company Alkermes has announced the success of its ALKS 5461 treatment in a Phase III study for the treatment …
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership

